Literature DB >> 1686585

CNQX, a new non-NMDA receptor antagonist, reduces spike wave discharges in the WAG/Rij rat model of absence epilepsy.

G M Ramakers1, B W Peeters, J M Vossen, A M Coenen.   

Abstract

The effects on seizures, EEG and behavior of the non-NMDA receptor antagonist CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), were studied in the WAG/Rij rat with absence epilepsy. Intracerebroventricular injections (10, 50, and 100 nmol/5 microliters CNQX) showed that CNQX decreases the number of spike wave discharges in a dose-dependent way. Coinjection of CNQX (100 nmol/5 microliters) and AMPA (0.1 pmol/5 microliters), kainic acid (0.01 nmol/5 microliters) or NMDA (50 pmol/5 microliters) attenuated the CNQX response, indicating that CNQX acts on both non-NMDA and NMDA receptors. The observed effects appear to be specific manipulations of the epilepsy not mediated by behavioral changes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686585     DOI: 10.1016/0920-1211(91)90023-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  NPY signaling through Y1 receptors modulates thalamic oscillations.

Authors:  Julia Brill; Gunnar Kwakye; John R Huguenard
Journal:  Peptides       Date:  2006-12-29       Impact factor: 3.750

2.  Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.

Authors:  A S Bazyan; G van Luijtelaar
Journal:  ISRN Neurol       Date:  2013-05-07

3.  PICK1 uncoupling from mGluR7a causes absence-like seizures.

Authors:  Federica Bertaso; Chuansheng Zhang; Astrid Scheschonka; Frédéric de Bock; Pierre Fontanaud; Philippe Marin; Richard L Huganir; Heinrich Betz; Joël Bockaert; Laurent Fagni; Mireille Lerner-Natoli
Journal:  Nat Neurosci       Date:  2008-07-20       Impact factor: 24.884

Review 4.  Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy.

Authors:  Roberta Celli; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.